N/A
Manufactured by INDIVIOR INC.
59,605 FDA adverse event reports analyzed
Last updated: 2026-04-14
BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by INDIVIOR INC.. The most commonly reported adverse reactions for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE include DRUG DEPENDENCE, DRUG WITHDRAWAL SYNDROME, PAIN, OFF LABEL USE, OVERDOSE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE.
Out of 23,702 classified reports for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 59,605 FDA FAERS reports that mention BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG DEPENDENCE, DRUG WITHDRAWAL SYNDROME, PAIN, OFF LABEL USE, OVERDOSE, NAUSEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list INDIVIOR INC. in connection with BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.